Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Gamberi, Barbara; Kyriakou, Charalampia; Ashcroft, John; Hernandez, Miguel; CAERS, Jo; Bos, Gerard; Echeveste, Maria Asuncion; Berthou, Christian; Zambello, Renato; Kuenburg, Elisabeth; Rosettani, Barbara; Ryder-Smith, Brooke; Blau, Igor

No full text

Poster (Scientific congresses and symposiums)

Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)

Gamberi, Barbara; Kyriakou, Charalampia; Ashcroft, John et al.

2012 • 54th ASH Annual Meeting

Permalink
https://hdl.handle.net/2268/161849

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Hematology

Author, co-author :

Gamberi, Barbara

Kyriakou, Charalampia

Ashcroft, John

Hernandez, Miguel

CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Bos, Gerard

Echeveste, Maria Asuncion

Berthou, Christian

Zambello, Renato

Kuenburg, Elisabeth

More authors (3 more)

Language :

English

Title :

Publication date :

2012

Event name :

54th ASH Annual Meeting

Event date :

du 8 décembre 2012 au 11 décembre 2012

Audience :

International

Available on ORBi :

since 22 January 2014

Statistics

Number of views

65 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics